Gantenerumab’s flop in Phase 3 means that lecanemab emerges as the preliminary favorite in the antibody class of biologics targeting beta-amyloid plaque in Alzheimer’s Disease patients. But, several key market access challenges lie ahead for the Alzheimer’s drug, should it get FDA approval in 2023.
Gantenerumab’s Phase 3 Flop Means Lecanemab Emerges As Favorite In Antibody Class Targeting Amyloid Plaque In Alzheimer’s Patients
